The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication. The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose mea

Global healthcare is a $12 trillion market carrying a 34-million worker shortage, yet healthtech captured just 5% of the $712 billion in global venture capital deployed in the first half of 2026. That gap, a trillion-dollar industry still treated as a rounding error by the venture industry, is the starting point for everything else here. We at Verge HealthTech Fund have always talked about how healthcare should transform from “sick-care” to “health + care.”

Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion. Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.

Capital follows vitality. Here is where the global longevity, investment, and high-performance ecosystem meets next.

Discover how the Basel Area and Roche are institutionalizing longevity as an asset class through a CHF 1.4B pivot into predictive, human-centric infrastructure.